Prolastin (Talecris Biotherapeutics C formerly Bayer): Full Drug Profile
- Prolastin (Talecris Biotherapeutics C formerly Bayer) – general information
- Pharmacology of Prolastin (Talecris Biotherapeutics C formerly Bayer)
- Prolastin (Talecris Biotherapeutics C formerly Bayer) for patients
- Prolastin (Talecris Biotherapeutics C formerly Bayer) interactions
- Prolastin (Talecris Biotherapeutics C formerly Bayer) contraindications
- Additional information about Prolastin (Talecris Biotherapeutics C formerly Bayer)
Prolastin (Talecris Biotherapeutics C formerly Bayer) - General Information
Human alpha-1 proteinase inhibitor or alpha-1-antitrypsin, prepared from human plasma via Cohn alcohol fractionation followed by PEG and zinc chloride fractionation.
Pharmacology of Prolastin (Talecris Biotherapeutics C formerly Bayer)
Prevents excessive accumulation of active neutrophil elastase and consequent proteolysis of elastin tissues in alveolar lung structures. This prevents the development of emphysema.
Prolastin (Talecris Biotherapeutics C formerly Bayer) for patients
Prolastin (Talecris Biotherapeutics C formerly Bayer) Interactions
Prolastin (Talecris Biotherapeutics C formerly Bayer) Contraindications
Zemaira™ is contraindicated in individuals with a known hypersensitivity to any of its components. Zemaira™ is also contraindicated in individuals with a history of anaphylaxis or severe systemic response to A1-PI products. Individuals with selective IgA deficiencies who have known antibodies against IgA (anti-IgA antibodies) should not receive Zemaira™, since these patients may experience severe reactions, including anaphylaxis, to IgA that may be present in Zemaira™.
Additional information about Prolastin (Talecris Biotherapeutics C formerly Bayer)
Prolastin (Talecris Biotherapeutics C formerly Bayer) Indication: For treatment of panacinar emphysema Mechanism Of Action: Alpha-1 proteinase inhibitor is a serine protease inhibitor (Serpin). It primarily inhibits the action of the serine protease called elastase (also plasmin and thrombin). The reactive center loop (RCL) of alpha-1 proteinase inhibitor extends out from the body of the protein and directs binding to the target protease. The protease cleaves the serpin at the reactive site, establishing a covalent linkage between the carboxyl group of the serpin reactive site and the serine hydroxyl of the protease. The resulting inactive serpin-protease complex is highly stable. Drug Interactions: Not Available Food Interactions: Not Available Generic Name: Alpha-1-proteinase inhibitor Synonyms: Alpha-1 protease inhibitor; Alpha-1-antiproteinase; Alpha-1-antitrypsin precursor; Alpha 1-antitrypsin Drug Category: Enzyme Replacement Agents Drug Type: Biotech; Approved Other Brand Names containing Alpha-1-proteinase inhibitor: Aralast (Baxter); Prolastin (Talecris Biotherapeutics C formerly Bayer); Absorption: Not Available Toxicity (Overdose): Not Available Protein Binding: Not Available Biotransformation: Not Available Half Life: Not Available Dosage Forms of Prolastin (Talecris Biotherapeutics C formerly Bayer): Injection, powder, lyophilized, for solution Intravenous Chemical IUPAC Name: Alpha-1-proteinase inhibitor Chemical Formula: C2001H3130N514O601S10 Alpha-1-proteinase inhibitor on Wikipedia: https://en.wikipedia.org/wiki/Alpha_1-antitrypsin Organisms Affected: Humans and other mammals
